Most Favored Nation Policy Is Unfavorable to U.S. Biopharmaceutical Research
Citizens Against Government Waste, by Elizabeth Wright
Back in September, President Trump signed an Executive Order ordering the Department of Health and Human Services to implement a most favored nation (MFN) policy for pharmaceutical reimbursement in Medicare. What this means is the U.S. would pay no more than the lowest price found in 14 countries, including Canada, England, Greece, Italy, and Japan. While that may sound like a good proposal to help reduce drug costs, it is not. These countries use the heavy hand of government to manage their healthcare and that includes price controls.